You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
SBC: Iveena Delivery Systems, Inc. Topic: NEIProject Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
SBC: SINTX TECHNOLOGIES, INC. Topic: NIAMSPROJECT SUMMARYSpinal fusion is the standard treatment for persistent neck and back pain, but the hardware used to stabilize the fusion can harbor or even promote bacteria that lead to persistent, difficult-to-treat infections that are costly and damaging to patient health. Among the available materials for spinal fusion, polyether-ether-ketone (PEEK) cages stand out due to their strength, biocomp ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
SBC: D BioTherapeutics, LLC Topic: NIAMSRheumatoid arthritis (RA) is a chronic, debilitating inflammatory disease with high medical and societal costs afflicting more than 1.6 million Americans. Blockade of TNFα-driven inflammation with approved anti-TNFα biologics (such as Humira®, Remicade®, Simponi®, and Enbrel®) is an effective treatment for many patients suffering from RA. However, due at least in part to the immunogenicity o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercial translation of high-density carbon fiber electrode arrays for multi-modal analysis of neural microcircuits
SBC: BLACKROCK MICROSYSTEMS, INC Topic: 106ABSTRACT The ability to measure and manipulate local brain circuit activity in living, behaving animals is essential to understanding the complexities of brain function and dysfunction. A novel, penetrating high-density carbon fiber electrode array composed of flexible, ultrathin conductive carbon microfibers was recently developed under the BRAIN Initiative to study neural microcircuit dynamics. ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis
SBC: GLYCOMIRA, LLC Topic: NIAIDPROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
CUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERS
SBC: Proactive Memory Services Topic: RCUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERSProject Summary/Abstract - ProActive Memory Services, Inc. New strategies are urgently needed to improve Alzheimer’s disease and related dementias (AD/RD) training for 4.6 million professional direct care providers that assist 8.3 million older adults in the US. Assisted living facilities (ALF) and personal care agenc ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility
SBC: INHERENT BIOSCIENCES, INC. Topic: NICHDNIH SBIR Fast-Track Application: Inherent Biosciences SUMMARY/ABSTRACT Title: Novel Epigenetic Test for the Treatment and Improvement of Longitudinal Health-Outcomes for Men with Severe Infertility39.7 million men worldwide (1% of the male population) suffer the severest form of male infertility: Non-Obstructive Azoospermia (NOA). These men have no identifiable sperm in their semen, greatly limiti ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Closed-loop laryngeal pacing for voice restoration
SBC: RIPPLE LLC Topic: NIDCDProject Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
High density chronic optogenetic interface for primate brains
SBC: BLACKROCK MICROSYSTEMS, INC Topic: 101PROJECT SUMMARY Understanding the function of neural circuits in the cerebral cortex of the non-human primate (NHP), the model system closest to human, is crucial to understanding normal cortical function and the circuit-level basis of human brain disorders. Optogenetics has become a powerful tool for studying neural circuit function, but challenges remain in its application to NHPs. Large volume ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
SBC: Curza Inc Topic: NIAIDProject Summary Cūrza is developing the CZ-02 platform of broad-spectrum antibiotics as a new class focusing on multidrug- resistant (MDR) Gram-negative pathogens that will also be efficacious against Gram-positive bacteria. CZ-02 antibacterials bind to a unique site on the bacterial ribosome that is not targeted by antibiotics available clinically which is expected to limit cross-resistance to o ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health